Summary of the Conference Call for Zhaoyan New Drug Company Overview - **Company**: Zhaoyan New Drug - **Industry**: Pharmaceutical and Laboratory Services Key Financial Performance - **Q1 Revenue**: 411 million CNY, a year-on-year increase of 115.11% [2][3] - **Net Profit**: 41.12 million CNY, with a non-recurring net profit of 25.66 million CNY [2][3] - **Laboratory Segment Loss**: 41.34 million CNY, attributed to quarterly factors and industry pressures [2][3] - **Biological Asset Value Change**: Gain of 53 million CNY [2] - **Funds Management Contribution**: 16.62 million CNY [2] Order and Client Status - **New Orders**: Approximately 430 million CNY in new orders, a year-on-year increase [2][3] - **Backlog**: 2.2 billion CNY in backlog, stable compared to the previous quarter [2][3] - **Order Cancellations**: Decreased significantly, indicating a return to normal client status [2][14] Industry Dynamics - **Domestic IND Growth**: Slowed to 2.54%, but remains at a high level with stable order prices [2][5] - **FDA Policy on Animal Testing**: Proposed to use AI and organoids as alternatives, with limited short-term impact; ongoing monitoring of policy developments is necessary [2][5] - **Monkey Prices**: Stable due to supply-demand balance; domestic supply remains tight [2][7][8] Capacity and Expansion - **Non-Clinical Business Utilization**: High capacity utilization; new facility in Guangzhou nearing completion [2][9] - **M&A Activity**: Focused on enhancing laboratory service capabilities, with ongoing domestic and international acquisitions [2][10] Financial Management - **Accounts Receivable**: Good condition with high client creditworthiness; collection pressure is low [4][19] - **Cost Control**: Emphasis on managing costs and improving operational efficiency [15] Market Outlook - **Profitability Pressure**: No specific guidance on gross margin and net profit due to market demand and pricing uncertainties [4][12] - **Competition**: Industry competition remains stable, with some small companies exiting the market [19] Additional Insights - **Order Execution Cycle**: Typically ranges from 6 to 12 months, with no significant backlog currently [15] - **Emerging Fields**: New segments are growing faster than traditional ones, indicating a shift in market dynamics [22] This summary encapsulates the key points from the conference call, highlighting the financial performance, order status, industry dynamics, capacity expansion, financial management, market outlook, and additional insights relevant to Zhaoyan New Drug.

NO.1 赛力斯向港交所递交上市申请 4月28日，港交所文件显示，赛力斯集团股份有限公司向港交所提交上市申请书。今年3月底，赛力斯就宣布拟赴港上市，其彼时表示，发行H 股股票并上市是为了深入推进全球化战略布局，打造国际化资本运作平台，提高综合竞争力。H股募资将用于新能源汽车技术研发、海外市场 拓展及供应链优化。 点评：此次赴港上市旨在打造国际化资本运作平台，提高综合竞争力。H股募资将用于新能源汽车技术研发、海外市场拓展及供应链优化，这 将有助于赛力斯在全球新能源汽车市场中占据更有利的位置。 NO.2 昭衍新药一季度业绩同比扭亏为盈 4月28日，昭衍新药（HK06127，股价15.26港元）公布2025年第一季度业绩，公司实现营业收入约2.87亿元，同比减少11.54%；归属于上市公司 股东的净利润约4111.95万元，同比扭亏为盈；基本每股收益0.05元。公告称，净利增长主要系上年同期生物资产公允价值变动损失较多所致。 点评：尽管昭衍新药一季度营业收入有所下降，但净利润实现扭亏为盈，主要得益于上年同期生物资产公允价值变动损失的减少。这表明公司 在成本控制和运营效率方面取得了一定成效。 NO.3 耀才证券金融复 ...

但随着这个瓜的剧情发酵，舆情开始关注起了那位被医生搞大肚子的董医生，她的经历有些特殊。 父亲是某央企的总经理\党委副书记（副厅级），母亲是北京211高校的副院长（副处级），女儿高中就去美国读书，之后在哥伦比亚大学读了 一个经济学本科。 到这其实都还算正常，但之后回国通过协和4+4项目，四年后获得医学博士学位（M.D.）。看到这估计很多人就懵逼了，之前还是经济学本 科，回国读4年就变成医学博士了？ 我一开始也以为是通过父母权力寻租开的后门，结果去搜了一下发现协和这个4+4项目，专门收 非医学 类本科毕业生，但是要求本科是全球前 100的名校毕业，这个董医生是符合的，另外需要有2位医学领域的副教授写推荐信，学费也不便宜，一年15万。每年招30-45人。 感觉这个项目...是专门给背景人士的孩子留的后门，海外本科和高昂学费把普通家庭筛掉了，还要2个副教授写推荐信，这要不是在那个圈子里 的可不好找。 普通医学生的路径是5+3+3，5年本科，3年专硕，后面再规培3年当苦力。相比之下这位董医生国外回来4年就拿到博士学位，规培时间也压缩 到1年，之后就临床做手术了，而且还是在北京知名医院工作，直接把普通医学生羡慕坏了。 最 ...

从交易标的看，朗研生命成立于2010年7月14日，是一家药物研发生产商，专注于高难度首仿药、创新药研发、生产、销售一体化 服务，在研产品管线覆盖了心脑血管、肿瘤、消化、感染等适应症。 需要指出的是，本次交易对方为利虔、赣州朗颐投资中心（有限合伙）等朗研生命股东，而阳光诺和的实际控制人也是利虔，因 此此次交易构成关联交易。 星标 ★ IPO日报 精彩文章第一时间推送 4月24日晚间，北京阳光诺和药物研究股份有限公司（以下简称"阳光诺和"，688621.SH）发布公告称，公司拟通过发行股份 及可转换公司债券方式购买江苏朗研生命科技控股有限公司（以下简称"朗研生命"）100%股权，并向不超过35名特定投资者 发行股份募集配套资金。 经初步测算，本次交易预计构成重大资产重组，且构成关联交易，本次交易不会导致公司实际控制人发生变更。公司股票自2025 年4月25日开市起开始停牌，预计停牌时间不超过5个交易日。 制图：佘诗婕 曾收购失败 反观上市公司本身，阳光诺和于2021年上市，是一家专业的药物临床前及临床综合研发服务CRO，为国内医药企业和科研机构提 供全过程的一站式药物研发服务，致力于协助国内医药制造企业加速实现进 ...

Core Viewpoint - Sunshine Nuohua plans to acquire 100% equity of Jiangsu Langyan Life Science Technology Co., Ltd. through share issuance and convertible bonds, constituting a major asset restructuring and related party transaction, with no change in actual control [1][3]. Group 1: Acquisition Details - The acquisition target, Langyan Life, established in July 2010, focuses on high-difficulty generic drugs and innovative drug R&D, with product pipelines covering cardiovascular, oncology, digestive, and infectious diseases [3]. - The transaction involves shareholders including Li Qian and Ganzhou Langyi Investment Center, with Li Qian also being the actual controller of Sunshine Nuohua, thus constituting a related party transaction [3]. - Previous attempts to acquire Langyan Life were unsuccessful, with a failed acquisition plan announced in October 2022 [4][5]. Group 2: Financial Aspects - The transaction price is set at 1.611 billion yuan, with an additional 1.007 billion yuan to be raised for cash consideration and project expansions [5]. - Langyan Life's revenue was 510 million yuan in 2021 and 617 million yuan in 2022, with net profits of 37.54 million yuan and 85.13 million yuan respectively [5]. - Performance commitments from the sellers include net profits of no less than 95 million yuan, 125 million yuan, and 158 million yuan for 2023, 2024, and 2025, totaling at least 378 million yuan [5][6]. Group 3: Strategic Intent - The acquisition aims to extend Sunshine Nuohua's main business into the CDMO sector, creating an integrated service platform for clinical research and customized production, enhancing competitive strength and strategic layout [7]. - Sunshine Nuohua, listed in 2021, provides comprehensive drug R&D services, assisting domestic pharmaceutical companies in achieving import substitution and innovation [7]. - Despite a projected revenue increase of 15.7% to 1.078 billion yuan in 2024, net profits are expected to decline due to rising fixed costs and increased R&D investments [8].

Core Insights - The company reported a revenue of 544 million yuan for 2024, representing a year-on-year growth of 11.18%, while the net profit attributable to shareholders decreased by 54.59% to 17.08 million yuan [1] - The company is a new drug research and development service provider, increasing its R&D investment, which amounted to 47.26 million yuan, accounting for 8.68% of total revenue [1] - The compound annual growth rate (CAGR) for revenue from 2022 to 2024 is 6.70%, while the CAGR for R&D expenses is significantly higher at 40.21% [1] R&D and Technical Platforms - As of the end of 2024, the company has delivered a total of 55 candidate drug molecules to clients, with 10 new additions compared to 2023, and 47 of these are First-in-Class (FIC) projects, making up 85.45% of the total [1] - The company has established 12 core technology platforms since 2019, including CADD/AIDD, enzyme chemistry, photochemistry, and others, to enhance its technological capabilities [1] Business Development - The CADD/AIDD technology platform has supported 80 new drug projects, with 6 entering clinical Phase I and 1 entering clinical Phase II, and the number of clients utilizing CADD/AIDD services has reached 40 [2] - The company has intensified its marketing and promotional efforts, participating in 19 domestic and international exhibitions and forums during the reporting period, leading to progress in active customer numbers and new order amounts [2] - The company provides comprehensive services for global pharmaceutical and biotechnology companies, focusing on drug discovery, pharmaceutical process development, and customized/commercial production of active pharmaceutical ingredients and key intermediates [2]

Core Viewpoint - The company Baicheng Pharmaceutical (301096.SZ) reported a significant decline in revenue and net profit for the year 2024 and the first quarter of 2025, indicating financial distress and operational challenges [2][3][4]. Financial Performance Summary - In 2024, the company achieved operating revenue of 802 million yuan, a decrease of 21.18% compared to 2023 [2][3]. - The net profit attributable to shareholders was -52.74 million yuan, a decline of 119.39% from the previous year's profit of 271.97 million yuan [2][3]. - The net profit after deducting non-recurring gains and losses was -72.63 million yuan, down 128.07% from 258.79 million yuan in 2023 [2][3]. - The net cash flow from operating activities was -195.86 million yuan, compared to a positive cash flow of 90.45 million yuan in the previous year, marking a 316.53% decrease [2][3]. Q1 2025 Performance Summary - For the first quarter of 2025, the company reported operating revenue of 129 million yuan, a decline of 40.32% year-on-year [4]. - The net profit attributable to shareholders was -26.20 million yuan, a decrease of 152.59% from the previous year's profit of 49.82 million yuan [4]. - The net profit after deducting non-recurring gains and losses was -36.18 million yuan, down 174.26% from 48.72 million yuan in the same period last year [4]. - The net cash flow from operating activities was -70.03 million yuan, an improvement of 42.59% compared to -121.98 million yuan in the previous year [4]. Stock Market Performance - Baicheng Pharmaceutical was listed on the Shenzhen Stock Exchange's ChiNext board on December 20, 2021, with an initial price of 79.60 yuan per share [5]. - The stock reached a high of 120 yuan on its first trading day but has since experienced a downward trend, currently trading below its initial offering price [4][5]. Fundraising and Use of Proceeds - The company issued 27.04 million shares, raising a total of 2.153 billion yuan, with a net amount of 1.863 billion yuan after deducting issuance costs [5][6]. - The final net fundraising amount exceeded the original plan by 1.213 billion yuan, with the funds intended for the headquarters and R&D center project in Hangzhou [5].

毕得医药(688073)近日召开了终止发行股份购买资产并募集配套资金事项投资者说明会，针对近期市场 关注的公司终止收购Combi-Blocks,Inc.股权事宜解答投资者提问。 今年1月，毕得医药公告，公司拟发行股份购买维梧(苏州)健康产业投资基金(有限合伙)、Vivo Cypress X,Co.Limited所持珠海维播投资有限公司的部分股权并募集配套资金，从而实现对最终目标公司Combi- Blocks,Inc.的控制。此次交易预计构成《上市公司重大资产重组管理办法》规定的重大资产重组。 毕得医药此前表示，此次交易高度契合上市公司全球化战略定位。公司将以加速全球化布局为战略目 标，致力于进一步实现市场全球化、资本全球化和人才全球化发展。 说明会上，毕得医药提到，此次收购终止不会影响既定的全球化战略布局。公司始终将全球化作为长期 发展战略，收购只是多种方式之一；同时，公司拥有快速反应的能力和多元化的实施方案，确保全球化 进程不受单一事件影响，对实现长期全球化发展目标充满信心。 就此次交易终止的影响，毕得医药从经营层面表示，该事项不会对公司的发展战略、经营规划造成重大 不利影响。未来公司将继续围绕既定的战略目 ...

（文章来源：每日经济新闻） 药明康德4月15日晚间发布公告称，无锡药明康德新药开发股份有限公司于2025年4月8日召开第三届董 事会第二十次会议，审议通过《关于2025年第二次以集中竞价交易方式回购公司A股股份的议案》。现 将公司2025年4月8日前十大无限售条件股东披露如下：HKSCC NOMINEES LIMITED持约3.87亿股，占 比13.4%（H股）；香港中央结算有限公司持约2.4亿股，占比8.31%；G&C VI Limited持约1.43亿股，占 比4.95%；G&C IV Hong Kong Limited持约1.05亿股，占比3.62%；北京中民银孚投资管理有限公司－嘉 兴宇祥投资合伙企业（有限合伙）持约8707万股，占比3.02%；G&C V Limited持约7311万股，占比 2.53%；中国工商银行－上证50交易型开放式指数证券投资基金持约4891万股，占比1.69%；中国工商 银行股份有限公司－中欧医疗健康混合型证券投资基金持约4610万股，占比1.6%；中国银行股份有限 公司－华宝中证医疗交易型开放式指数证券投资基金持约4601万股，占比1.59%；中国建设银行股份有 限公司－ ...

药明康德(02359.HK)：公司宣布将于2025年4月28日（星期一）召开董事会会议，以考虑及批准（其中 包括）本集团截至2025年3月31日止三个月之第一季业绩及其发布。 ...